AVXL regains Nasdaq compliance and refocuses on three core indications
AVXL says it regained Nasdaq compliance and addressed internal control weaknesses, focusing resources on Alzheimer's, Rett syndrome and fragile X syndrome. The company is advancing blarcamesine with regulatory engagement and improved transparency, while pausing less promising programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.